Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy.
Histone deacetylase inhibitors (HDACi) can induce human immunodeficiency virus (HIV) transcription from the HIV long terminal repeat (LTR). However, ex vivo and in vivo responses to HDACi are variable and the activity of HDACi in cells other than T-cells have not been well characterised. Here, we de...
Main Authors: | Hao K Lu, Lachlan R Gray, Fiona Wightman, Paula Ellenberg, Gabriela Khoury, Wan-Jung Cheng, Talia M Mota, Steve Wesselingh, Paul R Gorry, Paul U Cameron, Melissa J Churchill, Sharon R Lewin |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4237424?pdf=render |
Similar Items
-
10 Histone deacetylase inhibitors reduce proteins crucial to the elongation, splicing and nuclear export of HIV RNAs
by: Talia M. Mota, et al.
Published: (2017-07-01) -
A role for the histone deacetylase HDAC4 in the life-cycle of HIV-1-based vectors
by: Kao Gary D, et al.
Published: (2010-09-01) -
Synthesis of Sulfonamides and Evaluation of Their Histone Deacetylase (HDAC) Activity
by: Jae–Chul Jung, et al.
Published: (2007-05-01) -
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs.
by: Hugo Rolando Vaca, et al.
Published: (2021-03-01) -
Characterization of the human HDAC1, HDAC2, HDAC3, and chicken erythrocyte histone deacetylase activities
by: Moniwa, Mariko
Published: (2007)